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Key Messages
• Gastrointestinal adverse drug reactions (GADRs) such as diarrhea and constipation pose a genuine clinical issue
for drug discovery programs, prompting the need to design simple and reliable biomarkers of gastrointestinal
(GI) function.
• The main findings from this study were that a novel in-vitro bioassay and an established in-vivo charcoal meal
model were poor predictors of GADRs when both models were assessed using a series of 15 compounds
associated with/without clinical GADRs.
• Our observations suggest that improved models are required for safety pharmacology assessments of motility-
related GADRs.
Abstract
Background Motility-related gastrointestinal (GI)
adverse drug reactions (GADRs) such as diarrhea and
constipation are a common and deleterious feature
associated with drug development. Novel biomarkers
of GI function are therefore required to aid decision
making on the GI liability of compounds in develop-
ment. Methods Fifteen compounds associated with or
without clinical GADRs were used to assess the ability
of an in vitro colonic motility bioassay to predict
motility-related GADRs. Compounds were examined
in a blinded fashion for their effects on mouse colonic
peristaltic motor complexes in vitro. For each
compound concentration-response relationships were
determined and the results compared to clinical data.
Compounds were also assessed using GI transit mea-
surements obtained using an in vivo rat charcoal meal
model. Key ResultsWithin a clinically relevant dosing
range, the in vitro assay identified five true and three
false positives, four true and three false negatives,
which gave a predictive capacity of 60%. The in vivo
assay detected four true and four false positives, four
false and three true negatives, giving rise to a predictive
capacity for this model of 47%. Conclusions & Infer-
ences Overall these results imply that both assays are
poor predictors of GADRs. Further analysis would
benefit from a larger compound set, but the data show
a clear need for improved models for use in safety
pharmacology assessment of GI motility.
Keywords adverse drug reaction, bioassay, biomar-
ker, gastrointestinal motility, safety pharmacology.
Abbreviations: ADR, adverse drug reaction; AUC, area
under curve; CNS, central nervous system; CPMCs,
colonic peristaltic motor complexes; FN, false nega-
tive; FP, false positive; GADRs, gastrointestinal
adverse drug reactions; GI, gastrointestinal; IP, intra-
luminal pressure; TIQ, time in quiescence; TN, true
negative; TP, true positive.
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INTRODUCTION
Gastrointestinal adverse drug reactions (GADRs) repre-
sent around 67% of adverse drug reactions (ADRs)
described on drug labels1 and account for 23%of adverse
events encountered in phase I studies.2 Motility-related
GADRs such as diarrhea and constipation are common
side-effect profiles ofmarketed drugs,3–6 and account for
a high proportion of ADRs encountered during the
development of new chemical entities.7 Gastrointesti-
nal adverse drug reactions can be dose limiting precli-
nically and/or clinically, affect patient compliance, or
even lead to compound discontinuation.8 Conse-
quently, GADRs pose a genuine clinical issue and are
contributing to the escalating costs of developing new
drugs.9,10 Accurate and simple biomarkers of gastroin-
testinal (GI) function are therefore required to detect
potential GADRs earlier in the drug discovery pathway
and so maximize the opportunity to ‘design out’ this
undesirable characteristic, or to deselect compounds
from on-going development. Ultimately, this should
deliver new drugs that have improved patient compli-
ance and commercial attractiveness.
Presently, theGI tract is classified as a supplementary
organ system by the International Congress onHarmon-
isation (ICH) section 7A guidelines, the regulatory
requirement that must be fulfilled before testing novel
pharmaceuticals in humans. As a result, pharmaceutical
companies do not routinely assess the effect of new
chemical entities on the GI tract before clinical devel-
opment, and if they do, they are often not considered as
decisionmaking studies. However, the high incidence of
GADRs and their impact upon patient safety and com-
pliance, in addition to payer requirements and commer-
cial attractiveness, is now challenging this approach.
A number of in vivo and in vitromodels are available
to investigate GI function.11–14 In addition, newer
screening approaches have been proposed based on
zebrafish15,16 and more established rodent-based mod-
els.17 Recently, we described a novel in vitro bioassay
for use as a model of motility-related GADRs (diarrhea/
constipation). This bioassay employs segments of
mouse colon which generate robust and stereotypic
patterns of peristaltic motor complex activity when
mounted in an organ bath.18,19 Using a series of
compounds with well-validated GI motility-related
effects, we demonstrated that this model could poten-
tially aid GI safety pharmacology assessment. How-
ever, before routine use in a safety pharmacology
screening cascade, we wanted to investigate its utility
as an early hazard warning tool.
Therefore, the aim of this investigation was twofold:
(a) to determine the concordance, at clinically relevant
concentrations, between the in vitromouse bioassay and
phase I clinical outcome of compounds where the
molecular target was not necessarily associated with GI
motility and (b) to investigatewhether the invitromouse
bioassay performed any differently to the charcoal meal
test, the current method of choice for determining the
effects of compounds on GI transit in vivo in rodents.20
METHODS
Clinical studies
Fifteen compounds were used in this study, of which 13 were
proprietary AstraZeneca compounds, while the remaining two
were in clinical use (Table 1). Clinical data were gathered on these
compounds including GI symptoms, incidence, and plasma
exposure (Table 1).
Ethical approval for the assay development
All experimental procedures were conducted with local ethical
committee approval and in accordance with the UK Animals
(Scientific Procedures) Act, 1986 (National Archives, UK
Animals, Scientific Procedures Act, 1986) under the authority of
valid Home Office project licences.
In vitro colonic motility bioassay: experimental
protocol
These experiments were performed at the University of Sheffield.
Ninety-nine adult male mice (C57Bl/6J, bred in-house at the
University of Sheffield, Sheffield, UK), 6–8 weeks old and weigh-
ing ~24 g were used. Animals were housed under controlled
Table 1 Clinical data including type of GADRs, % of subjects affected,
and exposure range
Drug
Clinical
finding
% subjects
affected
Minimum and
maximum free
exposure range (lM)
B None 0 0.0024–0.6597
C Constipation 17 0.0010–0.0029
D None 0 0.0050–0.0352
E None 0 0.0060–2.6331
F Diarrhea 67 0.00007–0.6051
G* Diarrhea 53 6–12
H Diarrhea 17 0.0006–0.0710
I* Loose stools 25 0.7–18.9
J None 0 0.000008–0.0008
M Diarrhea 17 0.0017–0.0506
N* None 0 0.00014–0.0373
R None 0 0.000009–0.0837
S Nausea 13 0.000125––0.001
T Diarrhea 67 0.00935–0.1837
Z Loose watery
stools
100 0.00027–2
*Total plasma exposure. % affected is at the highest dose level. Free
exposure range refers to the mean exposure at the lowest and highest
dose tested clinically.
© 2014 The Authors.
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ambient temperature (21  2 °C) and light–dark cycle (12 : 12 h)
and were allowed free access to food and water.
The methodology has been described in detail previously.19
Briefly, animals were euthanized by cervical dislocation.
A midline laparotomy was immediately performed and the
exposed abdomen bathed in Krebs solution (in mM: 119 NaCl,
4.7 KCl, 1 NaH2PO4, 1.2 MgSO4, 25 NaHCO3, 2.5 CaCl2, 11
glucose) gassed with carbogen (95% O2, 5% CO2). The entire
colon was removed and immediately placed into a beaker of Krebs
solution. Using a syringe, the lumen was then cleared off any
contents by gentle flushing with Krebs solution. An adapted
standard organ bath procedure was used. Segments of colon (6 cm
length) were placed into the organ bath (20 mL volume) perfused
continuously (10 mL/min) with 37 °C Krebs solution, gassed with
carbogen, and equilibrated to pH 7.4. The oral and aboral ends of
the colon segment were securely attached to an input and output
port of the organ bath, respectively (Fig. 1A). The input port was
connected to a reservoir and syringe setup which allowed the
controlled perfusion of Krebs solution through the lumen of the
colonic segment, while the output port was attached in series to a
pressure transducer (BD DTXPlusTM, Oxford, UK). Motor activity
was initiated in the colon segments by an infusion of Krebs from
the syringe into the lumen of the colon until an intraluminal
pressure (IP) of ~5 mmHg had been reached. Under these condi-
tions, regular aborally propagating waves of contraction developed
spontaneously and persisted over time. These contractile waves
were recorded as changes in IP (Fig. 1B) and were termed colonic
peristaltic motor complexes (CPMCs), similar to the normal
peristaltic activity of the colon. After an equilibration period of
60 min, CPMC activity had reached a consistent pattern, in terms
of their amplitude and frequency, and experimental procedures
were then started. A very small number of tissues (~2% or less)
failed to show robust CPMC-like activity and these were
discarded from use before any experimental procedures took place.
In vitro bioassay: experimental procedure
Test compounds were bath applied using a cumulative concen-
tration-response protocol consisting of four successive 15-min
perfusion periods, starting with the vehicle and three incremental
concentrations of a drug, followed by a washout period to assess
the reversibility of effects. Compounds were tested at 0.3, 3, and
30 lM and their effects upon CPMC parameters were noted. If a
compound gave rise to significant excitatory or inhibitory effects
at the lowest concentration tested (0.3 lM), the concentration
range was reduced and experiments repeated using a cumulative
dosing procedure at the lower concentration range. This strategy
was repeated until a cumulative concentration-response effect for
each drug had been obtained. The concentration-range details for
these experiments are provided in Table 2 and Table S1. A series
of time-matched controls were also performed using serial
dilutions of DMSO in Krebs solution and the details of these are
also included in Table S1.
CPMC activity quantification
Colonic peristaltic motor complex activity was quantified using a
set of five parameters calculated for each 15-min experimental
phase of the cumulative concentration experiments. These were
as follows: CPMC frequency (number of CPMCs/15 min), the
average time interval between successive CPMCs (TI, s), the time
in quiescence (TIQ, s), which is a measurement of the total time
that the tissue is at baseline activity during the 15-min period of
drug or vehicle perfusion, the average CPMC amplitude (mmHg),
and the area under curve (AUC, mmHg/s) (Fig. 1B). The AUC and
amplitude reflected the mechanical activity of the tissue, whereas
the TIQ reflected the overall time with motor activity.
Data analysis
Changes in IP generated by CPMC activity were amplified
(Digitimer, NL108, Welwyn Garden City, UK) and subsequently
acquired to a computer through a CED 1401 interface and Spike2
software (Cambridge Electronic Design, Cambridge, UK). Intralu-
minal pressure was sampled at 100 Hz. Analysis was carried out
off-line using the software applications contained in the Spike2
software package. AUC was calculated using an in-built script in
the Spike2 software. Raw data are expressed as means  SEM and
compared by one-way ANOVA for repeated measures followed by
Dunnett’s test as appropriate. p < 0.05 was taken as significant.
100 s
20
mmHg
a
b
c1 c2 c3 c4 c5
c6
Krebs reservoir
Pressure
Transducer
Gassed Krebs 
Solution (37OC)Outflow from organ 
Bath to waste
Input port
Output portKrebs solution
colon
Oral Aboral
Carbogen input 
A
B
Figure 1 Representative trace of basal
murine colonic peristaltic motor complexes
(CPMCs). (A) Schematic diagram of the
in vitro organ bath experimental apparatus.
(B) The parameters used to evaluate changes
in motility are illustrated; a, interval
between successive CPMCs; b, amplitude of
individual CPMC; c1+c2+etc., time in
quiescence (TIQ). The AUC represents the
total area under the curve for the 15-min
analysis period, while the frequency
represents the number of CPMC measured
during this time period.
© 2014 The Authors.
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Data for TIQ and amplitude are also expressed as percentage
changes relative to their corresponding vehicles (relative changes),
and were compared to relative changes in TIQ and amplitude
calculated from time-matched vehicle control experiments. Com-
pounds which elicited relative changes in either CPMC amplitude
or TIQ that were >2 SD from the mean time-matched control
values were taken as positive responding compounds. Relative
changes above 2 SD were used as a decision criterion due to the
small range of TIQ and amplitude values observed in the
time-matched controls and compound experiments.
Drugs
All compounds were obtained from AstraZeneca in coded vials
and were tested in a blinded fashion (the number of experiments
conducted is indicated in parentheses in Tables 2 and 3). Stock
solutions of 1 or 10 mM were prepared by adding an appropriate
volume of either H2O or DMSO and were diluted to test
concentrations in Krebs solution. The maximum concentration
of DMSO used was 0.1%. Drugs were applied to the serosal
surface and while the bath concentrations of each compound were
not measured during the experiments, they were assumed to reach
a steady-state concentration equal to that of the perfusate.
Charcoal meal in vivo test: experimental protocol
These studies were performed at AstraZeneca R&DAlderley Park,
UK. Male Han Wistar rats weighing between 230 and 270 g
(AstraZeneca Breeding Unit, Alderley Park, UK or Harlan
Laboratories UK Ltd, Bicester, Oxon, UK) were housed in groups
of 4 with free access to food and water. Animals were housed
under ambient temperature (19–23 °C), relative humidity (40–
70%), and a 12-h light/dark cycle. At the start of the 6-h fasting
period, animals were placed in cages with a grid floor. The
measurements of GI function were performed in the afternoon
(~14:00 h) and the time of food removal was altered to fit the
designated fasting period accordingly.
Charcoal meal in vivo test: drugs and
experimental procedure
The methodology for the in vivo testing has been described
previously.17 All compounds were administered orally (dose
levels are indicated in Table S2). At the approximate Tmax of
each individual compound, animals were administered a charcoal
meal (activated charcoal; Sigma, Poole, Dorset, UK) formulated as
a suspension in 2% w/v carboxymethylcellulose (10 : 90). Fifteen
to 20 min later, they were killed by an overdose with halothane
followed by exsanguination. Following midline laparotomy, the
esophagogastric (cardia), gastroduodenal (pyloric sphincter), and
ileo-cecal junctions were ligated, and the stomach and small
intestine carefully removed from the esophagogastric to the ileo-
cecal junction. Each stomach, including contents, was weighed
and then cut open and rinsed with physiological saline. Excess
moisture was removed by gentle sponging with laboratory tissue
and the empty stomach weighed. Index of gastric emptying
(g) = full stomach weight (g)  empty stomach weight (g). The
entire small intestine was gently stretched out and the total
length measured. The distance traveled by the charcoal meal
from the pyloric sphincter to the ileo-cecal junction was
measured.
Intestinal transit quantification and data analysis
Intestinal transit was defined as the position of the leading edge of
the charcoal expressed as a percentage of the total length of the
small intestine, calculated as follows: Intestinal transit distance
(%) = [distance traveled by charcoal (cm)/length of small intestine
(cm)] 9 100.
The results from the charcoal meal were expressed as medians.
A non-parametric test (Wilcoxon Mann–Whitney test) was used to
compare the compound-treated groups with the vehicle-treated
group, as the distribution of the data was unknown. p < 0.05 was
taken as significant. Where possible, free plasma concentrations
were calculated, but for three compounds (G, I, and N), the plasma
Table 2 Summary data for test compounds examined in the in vitro
assay with comparison to clinical data
Drug
Drug
concentration
tested in
assay (lM)
Clinical
finding
Predictive
outcome
maximum
dose
Predictive
outcome
therapeutic
dose
B (N = 8) 0.3–30 NE FP FP
C (N = 6) 0.003–0.3 C TP TP
D (N = 6) 0.3–30 NE FP TN
E (N = 6) 0.3–30 NE FP FP
F (N = 6) 0.3–30 D TP TP
G (N = 7) 0.3–30 D FN FN
H (N = 7) 0.3–30 D TP TP
I (N = 7) 0.3–30 D FN FN
J (N = 6) 0.03–3 NE FP FP
M (N = 6) 0.3–30 D TP FN
N (N = 6) 0.3–30 NE FP TN
R (N = 6) 0.3–30 NE TN TN
S (N = 4) 0.3–30 NE FP* TN*
T (N = 6) 0.3–30 D TP TP
Z (N = 6) 0.3–30 D TP TP
*Minimum testing concentration was 9300-fold plasma exposure. C,
constipation; D, diarrhea; TN, true negative; TP, true positive; FP, false
positive; FN, false negative; NC, no change; NE, no effect.
Table 3 Summary data for test compounds examined in the charcoal
meal assay with comparison to clinical data
Drug
Drug
concentration
measured in
model (lM)
Charcoal
meal
effect*
Clinical
finding
Predictive
outcome
B (N = 10) 0.08–22 Decrease NE FP
C (N = 8) 0.06–0.58 NC C FN
D (N = 8) 0.196 NC NE TN
E (N = 8) 0.28–5.38 Decrease NE FP
F (N = 8) 0.072–0.183 Decrease D TP
G (N = 8) 1.67–468 Decrease D TP
H (N = 8) 0–0.0014 Decrease D TP
I (N = 8) 11.3–189 Decrease D TP
J (N = 8) 0.012–0.034 Decrease NE FP
M (N = 8) 69 Decrease† D FN
N (N = 8) 0.44 NC NE TN
R (N = 8) 0.06–10 NC NE TN
S (N = 8) 0–0.0000273 Increase NE FP
T (N = 10) 15–344 NC D FN
Z (N = 10) 0–23 NC D FN
*Data refer to the assay effects recorded at testing concentrations of
<50-fold the equivalent plasma exposure. †Only one dose tested at an
exposure of 69 lM (>1000-fold the equivalent plasma exposure).
Abbreviations are the same as for Table 2.
© 2014 The Authors.
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protein binding was not known (but thought to be negligible) and
therefore, the plasma exposure data are shown as a total value.
Assay quantification
The compounds tested in the two assays were assigned to the
following categories by comparing their experimental effects to
their clinical effects. To avoid any potential bias, the clinical
effects of these compounds were withheld from the investigators
until after the CPMC and intestinal transit quantification stages
were completed. The categories were as follows: true positives
(TP) were compounds which caused GADRs and elicited relative
changes to either CPMC amplitude or TIQ that were >2 SD from
their mean control values, or caused significant changes to
intestinal transit. False negatives (FN) were compounds which
caused GADRs and elicited relative changes in amplitude or TIQ
that were within 2 SD of their mean control values, or had no
significant effect on intestinal transit. True negative (TN)
compounds did not cause GADRs or elicit changes in either
relative CPMC activity or intestinal transit activity that indicated
positive compound effects. False positives (FP) are compounds
which possessed no clinically detected GADR activity, but
elicited changes in relative CPMC activity or intestinal transit
that were indicative of positive compound effects.
The predictive capacity (defined as the proportion of correctly
identified results) was calculated as follows: Predictive capac-
ity = (TP+TN)/total number of compounds tested.21,22
RESULTS
Clinical effects of the compounds
Clinical data were gathered on 15 compounds, includ-
ing 13 proprietary AstraZeneca compounds, and two
compounds currently used in clinical settings. Eight of
the compounds caused diarrhea or constipation affect-
ing between 17% and 100% of the patients, while
seven had no reported GADRs such as diarrhea or
constipation although one, rimonabant (Compound S),
was reported to cause nausea (Table 1).
CPMC activity
Baseline data on CPMC activity (collected over a 15-
min period from a total of 99 experiments) are
summarized as follows: frequency (the number of
CPMCs/900 s), 5.6  0.15; TI (the time between indi-
vidual CPMCs), 161.4  4 s; TIQ, 661  6 s;
amplitude (CPMC amplitude), 49  1.5 mmHg; AUC
(total activity during 900-s period, AUC),
6410  307 mmHg/s.
Compound effects upon CPMC activity
The 15 compounds were tested in a blinded fashion
for their effects upon CPMC activity. Two com-
pounds (C and J) elicited effects at the lowest dose
tested and were retested using a lower dosing strategy.
The remaining compounds were tested using the
standard dosing regimen. The raw data from these
experiments are summarized in Table S1 and an
illustrative example is shown in Fig. 2. The actions
of the test compounds upon CPMC amplitude and
TIQ were also plotted as percentage changes relative
to the vehicle response (relative change) and were
compared to appropriate time-matched controls
(Fig. 3).
Effect of drugs on relative changes in CPMC
parameters
At thehighest drug dose tested, nine compounds elicited
relative amplitude changes greater than 2 SD of the
mean amplitude change for time-matched controls
(Fig. 3A). A further three compounds elicited relative
amplitude changes greater than 1 SD of the mean
control amplitude change, while three compounds had
effects indistinguishable from control amplitude values
(Fig. 3A). A similar analysis of the TIQ data showed that
10 compounds gave rise to relative changes in TIQ > 2
SD of the mean TIQ change for time-matched controls
(Fig. 3B). Two compounds elicited effects that were
greater than 1 SD of the mean control amplitude
change, while three compounds had effects that were
indistinguishable from controls (Fig. 3B).
Effects of test compounds on relative changes at
therapeutic concentrations
Relative changes in TIQ and amplitude were also
assessed within clinically relevant concentrations
(defined as concentrations within 50-fold of the max-
imum plasma exposure recorded in the clinical trials).
When relative amplitude and TIQ changes were
assessed at the highest clinically relevant dose tested,
three compounds (B, F, and T) elicited relative ampli-
tude changes and seven compounds (B, C, E, F, H, J, and
Z) elicited relative TIQ changes that were greater than
2 SD from their mean time-matched control changes.
Several of the remaining compounds (D, M, and S)
elicited relative changes in one of the parameters that
was greater than 1 SD amplitude of the mean time-
matched control data, while compounds G, I, N, and R
gave rise to responses that were indistinguishable from
time match control data.
CPMC assay translation
The compounds’ effects on relative changes to either
amplitude or TIQ were compared to their clinical
© 2014 The Authors.
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actions and the predictive capacity of the assay calcu-
lated. The assay was found to have a predictive
capacity of 47% at the maximum drug concentration
tested and where the effect of drug exceeded 2 SD of the
control. This reflected the identification of 6 TPs, 2
FNs, 1 TN, and 6 FPs (Table 2). However, at the
clinically relevant concentrations, the assay identified
5 TPs, 3 FNs, 4 TNs, and 3 FPs, which gave a predictive
capacity of 60% (Table 2). A contingency analysis of
these results revealed no significant differences
between the two data sets (p > 0.05).
Effects of compounds on the in vivo charcoal
meal model
Based on an internal AstraZeneca database, the base-
line median small intestinal transit time of rats
(n = 287) fasted for 6 h, and treated with a vehicle,
prior to a charcoal meal was 53.3  12.2%.23 Of the 15
compounds tested in the in vivo charcoal meal study,
eight compounds (B, E, F, G, H, I, J, and S) caused
significant changes in intestinal transit at clinically
relevant concentrations (defined as concentrations
within 50-fold of the maximum plasma exposure
recorded in the clinical trials) and these data are
recorded in Table 3 and Table S2. Only compound S
stimulated intestinal transit, while the remaining
A
B
Figure 3 (A) Colonic peristaltic motor complex (CPMC) amplitude for
test compounds plotted as relative changes in amplitude at their
maximum dose compared to vehicle. Compounds are plotted alongside
appropriate time-matched vehicle control data (N = 4). (B) Similar
analysis for time in quiescence (TIQ) in which relative TIQ values for
the test compounds are plotted alongside appropriate time-matched
control data. Red bars indicate compounds associated with GADRs.
Green bars represent compounds with no GADRs reported. Black
dashed line represents 2 SD difference from the mean value. Blue
dashed line represents 1 SD difference from the mean control value.
Vehicle 0.3 μM 3 μM 30 μM
10
mmHg
400 s
A
B
E F
C D
Figure 2 Effects of Compound H upon
colonic peristaltic motor complex (CPMC)
activity. (A) Representative recording
showing the effects of cumulative additions
of Compound H upon CPMC activity.
Downward arrow represents start of
washout period. CPMC activity is decreased
in a concentration-dependent fashion. (B–F)
Illustrate the concentration-dependent
effects of Compound H (n = 7) on the
frequency (B); the time between consecutive
CPMCs (C); time in quiescence (TIQ; D); the
amplitude of CPMCs (E); and the AUC
(F). Data are expressed as mean  SEM;
*p < 0.05; **p < 0.01 vs control by repeated
measures one-way ANOVA.
© 2014 The Authors.
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compounds were associated with inhibition (Table 3
and Table S2). Five compounds (D, N, R, T, and Z) had
no effect upon intestinal transit, while two compounds
(C and M) inhibited intestinal transit, but at doses >50-
fold the maximum plasma exposure (Table 3 and
Table S2). Several of these compounds were examined
for their effects upon gastric emptying and we found
that all the compounds tested in this group altered
gastric emptying (Table S2).
Charcoal meal assay translation
An analysis was performed for the charcoal meal test in
which 4 TPs (Compounds F, G, H, and I), 4 FNs
(Compounds C, M, T, and Z), 3 TNs (Compounds D, N,
and R), and 4 FPs (Compounds B, E, J, and S) were
identified, giving rise to a predictive capacity for this
model of 47% (Fig. 3, Table 3).
DISCUSSION
This study set out to determine the translational
potential of a mouse in vitro bioassay and evaluate
its potential as an early screen to detect GI liability in
novel compounds. We focused on analyzing relative
changes in either amplitude or TIQ to assess the
predictive capacity of the model during the course of
this study. Measuring amplitude gave an indication of
the effects of the compounds upon CPMC contractil-
ity, while TIQ assessed the pattern of CPMC activity.
We focused upon using TIQ as a metric as our previous
study showed that TIQ was a robust and stable marker
of CPMC frequency.19 In our initial screen in which
absolute changes in CPMC activity were determined,
it was revealed that all the compounds significantly
affected amplitude at the highest drug dose tested.
However, we were mindful of over interpreting these
data as time-matched control experiments also
revealed a small but significant time-dependent change
in amplitude. This led to concerns that these time-
dependent amplitude changes were confounding the
drug-induced effects on this parameter, and so by
plotting relative changes in CPMC amplitude and
comparing these to equivalent time-matched controls,
we were able to control for these confounding factors.
Initially, the predictivity of the assay was deter-
mined using relative changes observed at the highest
dose tested. This may seem counter intuitive as we
knew the plasma exposures measured in the phase I
studies, but this assay was designed as an early safety
screen in which the therapeutic exposures of test
compounds would not be known. Consequently, we
wished to observe whether the assay would be effective
at the upper limit of testing conditions. Under these
conditions, the assay was found to have a predictive
capacity of 47%, while at clinically relevant exposures,
the predictive capacity was 60%. The difference
between these two assessments reflected an increased
number of FPs detected at the high testing concentra-
tions, although no significance was found between the
two methods of analysis.
Overall the predictive capacity of the assay was
considered ‘insufficient’ according to the European
Centre for the Validation of Alternative Methods
criteria for validating in vitro toxicology screening
methods21 and most likely reflect the fact that the low
sensitivity and specificity of the assay (the relatively
high proportion of FNs and FPs detected) impacted
negatively upon its validity as an early screening
model.
In vitro assays have several advantages for screening
such as relatively low costs and a capacity for medium
to high throughput testing. However, their predictive
capacity may be limited by their incomplete physiolog-
ical nature. For example, the isolated colon lacks central
nervous system neuronal influences, in addition to
systemic hormonal or metabolic influences and as such
the in vitro assaymeasures direct actions of compounds
upon colonic motility. Therefore, compounds which
cause changes in motility through centrally mediated
pathways would have no effect in this model. This is
illustrated in the results of Compound Gwhich was the
drug metformin and was one of only two of the
compounds whose identity was revealed in this study.
Metformin is a hypoglycemic agent used to treat type 2
diabetes.24,25 Its clinical use is associated with dose
dependentGI disturbances including diarrhea,26 and the
mechanisms contributing to this GI dysfunction are
thought to involve metabolic and centrally mediated
effects.27
We found that metformin had no significant effect
upon CPMC activity, but caused diarrhea in 53% of the
subjects tested. Consequently, Compound G was
incorrectly identified as a FN. These findings highlight
an important limitation inherent in all in vitro assays
in that compounds which produce their effects via
centrally mediated mechanisms would have no effect
in these in vitro models, but they could be detected
using appropriate in vivo techniques. Interestingly,
when this same compound was tested in the charcoal
meal model, the correct phenotype was identified
demonstrating a need to employ complementary
screening strategies throughout the drug discovery
process.
Despite these limitations, we did find that the in
vitro assay detected ‘high-incidence’ compounds better
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than ‘low incidence’ compounds. Four of the eight
compounds associated with causing GADRs affected a
high percentage of the patients (>50% affected), while
the remaining compounds were associated with lower
incidences (<25% of the cohort affected). The assay
correctly identified three of these ‘high-incidence’
compounds, while in the ‘low incidence’ category,
only two compounds were correctly identified. It is
likely that other factors contribute toward these low
incidences of GADRs including stress, diet, or
environmental factors and these cannot be modeled
in vitro. Two of the compounds associated with high
incidence of GADRs (Compounds T and Z) were
withdrawn from development due to their side effects
and both these compounds were flagged by the assay as
having potential GI liabilities. Therefore, despite the
limitations associated with this assay, it appears that
this model does have the capacity to act as a hazard flag
in certain situations, and as such could form a useful
addition to a battery of GI-orientated safety screens.
This study showed that only Compound Z increased
CPMC activity, in accordance with its diarrheal phe-
notype, while for the remaining compounds, CPMC
activity was decreased, even if diarrhea was the clinical
response to exposure of these drugs. While we would
have expected compounds causing diarrhea to be
associated with increased CPMC activity, so to drive
increased propulsion, contractions can both propel and
impede flow. As such, we sought only to determine if a
quantifiable change in CPMC activity could be
detected, and the extent to which this was correlated
with GADRs irrespective of whether this was consti-
pation or diarrhea.
The concentration relationship between the clinical
settings and the assay is important in determining
safety margins. We used a 50-fold margin between the
minimum assay drug concentration required to elicit
significant responses and the maximum plasma con-
centration achieved in patients as a therapeutic win-
dow to ensure relevant safety margins and also limit
the risk of obtaining FPs. This range corresponds to
limits set in other, notably cardiovascular, safety
models that suggest a 30-fold margin between the
highest free plasma concentration of a drug and safety
assay responses were adequate for this purpose.1,23,28
Interestingly, Compound I was tested at a maximum
concentration that was only twofold greater than the
maximum therapeutic dose used, and it is conceivable
that this dose was too low to cause any significant
effects upon CPMC activity which may explain the FN
phenotype associated with this compound.
Seven of the compounds tested in this study had no
GADRs associated with them, and using our therapeu-
tic dosing limits the assay correctly identified four of
these compounds as TNs. It is important to note that
while these compounds did alter CPMC activity, these
effects were seen at dosing margins of above 100-fold,
and in some cases greater than 1000-fold. However,
three compounds (B, E, and J) elicited effects upon
CPMC activity at clinically relevant doses and were
designated as FPs. False positives are a major issue for a
safety screen as it can lead to the discontinuation of
safe compounds which could potentially be life-saving
medicines. Both models identified compounds B, E,
and J as FPs suggesting that physiological pathways
present in rodents, but absent in humans contribute to
this difference. In the absence of any pharmacological
knowledge of these compounds, we cannot speculate
on why these results occurred, but they reflect the
importance of designing safety screening systems to
counteract possible species-related differences in the
drug target biology.
The results from this study suggested that the in
vitro assay lacks the overall predictivity to be utilized
as a screening model. We were also able to test the
clinical compounds using the charcoal meal test,11 the
current gold standard in safety assessment testing, and
surprisingly we found that this assay was also a poor
predictor of GADRs in the clinic. Direct comparisons
of the two models were avoided as they were performed
in different species, but the charcoal meal test likely
possesses some inherent experimental advantages over
an in vitro technique such as being capable of detecting
compounds acting via central processes. However, the
in vitro assay also offers some experimental benefits.
For example, the in vitro assay allows a more thorough
physiological assessment of drug-induced changes in
motility (amplitude vs pattern of activity as opposed to
overall transit) than the in vivomethod, and this could
provide valuable information to the mechanisms
through which compounds are affecting motility. This
was clearly demonstrated in our previous study in
which compounds could be discriminated by the in
vitro model as myogenic or neurogenic activators.19
Conclusion
Fifteen marketed drugs or drugs intended for market,
which are associated with or without GADRs, were
tested in a blinded manner in an in vitro bioassay
which we proposed as a biomarker for predicting the
GADR liability of new chemical entities. The in vitro
assay performed similarly to an in vivo model in
detecting compounds associated with GADRs in phase
1 trials, and while the in vitro assay shows some
promise in detecting high risk compounds, currently
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both techniques are unacceptable in terms of their
overall accuracy as stand-alone bioassays to detect
GADRs. Consequently, more efforts are needed to
develop suitable assays, or possibly a combination of
assays, to detect the GI motility liability of novel
compounds in development.
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